A
Apriori Bio
A health security company creating a world where humanity is protected against viral threats
About Apriori Bio
Apriori Bio is a forward-thinking biotechnology startup focused on combating viral threats through innovative technology. The company operates in the health security and biotechnology market, primarily serving pharmaceutical companies, healthcare providers, and government health agencies. Apriori Bio's unique platform leverages advanced computational science and biological insights to predict which virus variants pose the greatest threat. This allows them to design medicines, such as vaccines and antibodies, that are effective against these predicted variants.
Read full description
The business model of Apriori Bio revolves around the development and licensing of its proprietary technology and products. By partnering with pharmaceutical companies and healthcare organizations, Apriori Bio can bring its predictive and preventive solutions to market. The company generates revenue through licensing fees, research and development collaborations, and potentially through the sale of its own branded medicines in the future.
Apriori Bio's mission is to create a world where humanity is protected against viral threats. They achieve this by staying agile, bold, and dedicated to their scientific approach. Their meticulous and rigorous methods ensure that they stay ahead of evolving viruses, which are known to outwit immune systems and outpace traditional medicine development efforts. By reimagining vaccine and antibody design, Apriori Bio aims to provide actionable real-time insights and variant-proof medicines.
In summary, Apriori Bio is pioneering a new way to protect against constantly evolving viral threats. Their innovative approach has earned them recognition, including being featured on Fast Company's 2023 Innovation By Design Pandemic Action List and being named a Technology Pioneer by the World Economic Forum.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Cambridge, United States
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 74.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Apriori Bio.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jul 2024 | $1.1M | — | Coalition for Epidemic Preparedness | ↗ |
| EARLY VCOther financing | Jul 2022 | $50M | $200M | Flagship Pioneering | ↗ |
Growth signals
Latest recorded traffic for Apriori Bio is 4.3K monthly website visits, up 7.5% over the last three months. Apriori Bio's team grew 4.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Coalition for Epidemic Preparedness
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Apriori Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Apriori Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.